Scientific research teams in California and Texas have been awarded nearly $1.4 million in grants to study ways to improve pediatric heart transplant outcomes.
As Earth Day approaches, a promising startup that grew out of University of Delaware research is on the cusp of making sustainable green hydrogen a reality. Versogen, a UD spinoff company led by Professor Yushan Yan, is one of three startups selected for the fourth cohort of the Shell GameChanger Accelerator (GCxN) program.
A team of researchers from Dartmouth has been awarded nearly $225,000 from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to develop and test "BandPass," a remote-sensing resistance band exercise system that would allow health care providers to monitor, evaluate, and guide patients as they use the device in their homes.
Amid the rise in opioid overdoses during the COVID-19 pandemic, a University of Houston researcher has joined a team developing a vaccine for opioid use disorder. The vaccine targets fentanyl, a synthetic and very potent opioid, often added into street drugs.
The Andrew W. Mellon Foundation has approved a grant of $1.2 million to extend the Mellon Collaborative Studies in Architecture, Urbanism and the Humanities (AUH) interdisciplinary seminar series at Cornell University for three years with a focus on social justice.
The University of Houston has received a nearly $1.35 million grant from The Andrew W. Mellon Foundation to establish a free, open-access digital portal for anyone to learn about or teach Puerto Rican literature.
Southwest Research Institute has been awarded a grant from the Federal Aviation Ad-ministration (FAA) to continue a research program to improve the safety of commercial aircraft engines. The grant is planned to be a four-year, $4.5 million cooperative agreement to develop improved damage tolerance and risk assessment methods for critical life-limited engine parts.
Researchers from Aarhus University and Aarhus University Hospital replace sick intestinal bacteria with intestinal bacteria from healthy donors in a treatment intended to help patients with cirrhosis of the liver. The Novo Nordisk Foundation supports the project with just over DKK 13 million.
Stand Up To Cancer® (SU2C) and Mirati Therapeutics Inc. (NASDAQ: MRTX) - a late-stage targeted oncology company - announce that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.
People with cystic fibrosis are living better and longer, and now investigators want to further enhance quality and longevity by better understanding the role of nutrition, body composition and exercise in their health across an increasing lifespan.